Stomach carcinoma in situ

Summary

Stomach carcinoma in situ (MONDO:0004716) is a cancer. A subtype of in situ carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	stomach carcinoma in situ
Mondo ID	MONDO:0004716
DOID	DOID:9138
ICD-10-CM	D00.2
ICD-11	2040861039
NCIT	C7788
SNOMED CT	92756002
UMLS	C0154060
MedGen	56333
GARD	0027704
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of stomach · carcinoma in situ of the stomach · carcinoma of stomach stage 0 · carcinoma of the stomach stage 0 · gastric carcinoma in situ · gastric carcinoma stage 0 · gastric carcinoma, stage 0 · stage 0 carcinoma of stomach · stage 0 carcinoma of the stomach · stage 0 gastric (stomach) cancer · stage 0 gastric cancer · stage 0 gastric cancer aJCC v6 · stage 0 gastric cancer aJCC v6 and v7 · stage 0 gastric cancer aJCC v7 · stage 0 gastric carcinoma · stage 0 gastric carcinoma in situ · stage 0 stomach cancer · stage 0 stomach carcinoma · stomach carcinoma in situ · stomach carcinoma stage 0 (+1 more)

Disease family

This is a subtype of in situ carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › stomach carcinoma in situ

Related subtypes (20): oral cavity carcinoma in situ, pharynx carcinoma in situ, gall bladder carcinoma in situ, adenocarcinoma in situ, nasal cavity carcinoma in situ, skin carcinoma in situ, breast carcinoma in situ, eye carcinoma in situ, lung carcinoma in situ, squamous carcinoma in situ, larynx carcinoma in situ, intestine carcinoma in situ, bladder carcinoma in situ, esophagus carcinoma in situ, uterus carcinoma in situ, liver carcinoma in situ, kidney carcinoma in situ, grade III prostatic intraepithelial neoplasia, carcinoma in situ of ureter, carcinoma in situ of urethra

Subtypes (3): carcinoma in situ of fundus of stomach, carcinoma in situ of gastric body, carcinoma in situ of gastric cardia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.